Cytokinetics to Announce Results from BENEFIT-ALS at 66th Annual Meeting of the American Academy of Neurology

Cytokinetics, Incorporated announced today that results from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) will be presented during a Platform Session scheduled at the 66th Annual Meeting of the American Academy of Neurology (AAN) to be held April 26 – May 3, 2014 at the Pennsylvania Convention Center in Philadelphia, PA.

Research and Markets: Global Amyotrophic Lateral Sclerosis Market Forecast 2014-2018

The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services.

The RASCALS Board of Directors Salutes Its Remarkable RASCALS Volunteers

Robert Stehlin and the entire Board of Directors would like to once again recognize the tremendous efforts of our RASCALS Volunteer Army.

The 2014 RASCALS Foundation Higher Education Scholarships

The RASCALS Foundation is pleased to announce that it is once again offering  the 2014 Higher Education Scholarship Program to assist families affected by ALS.
We would like to acknowledge and thank our newest partner Helping Hands for ALS, a student group associated with John Burroughs High School for their generous participation in making these important [...]

Final Results of ALS Phase I Stem Cell Trial Published in Annals of Neurology

The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy in ALS patients.


Due to unforeseen scheduling conflicts, the RASCALS Foundation regrets to announce that its 3rd Annual 5K Walk/Run has been postponed to a later date.

Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats

The researchers concluded that the NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients

BrainStorm and Mass General Sign Definitive Agreement for ALS Clinical Trial

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS).

ALS Takes a Deep Breath with Diaphragmatic Pacing System

Traditionally, ALS patients like Mary would use a BiPAP machine to help her breathe. She’d wear a mask, tethered to a ventilator. It would force air into Mary’s lungs. Now, Mary is the first ALS patient at The Ohio State University to be implanted with a diaphragmatic pacing system to help her strengthen her muscles.

New Gene Variant Discovered for ALS

Research led by King’s College London has identified a new genetic variant, located on chromosome 17, associated with sporadic amyotrophic lateral sclerosis (ALS) – the most common form of motor neurone disease (MND).